Recent developments highlight RemSleep's management changes, product launch, and strategic commercial initiatives.

• RemSleep announced the passing of founder Thomas Wood and appointed Jeffrey Marshall as CEO in March 2026 [N6].
• The company announced the full commercial launch of its DeltaWave(TM) CPAP nasal pillows system in February 2026 [N7].
• RemSleep outlined its Q1 2026 commercial strategy focusing on expanded FDA applications, B2B launch preparation, and institutional market entry [N8].
• The company transitioned its business model from a retail walk-in approach in Georgia to e-commerce and distributor partnerships with a new warehouse in Florida [S2].
• Financial filings as of March 31, 2026, show cash and equivalents of $87,953, current assets of $160,809, current liabilities of $342,275, a current ratio of 0.47, and a net loss of $289,924 for Q1 2026 [S2].
• No material legal proceedings or claims are pending against the company or its officers [S1].

The company has achieved FDA clearance and launched its DeltaWave CPAP nasal pillows system commercially, indicating progress in product development and regulatory compliance. Transitioning to e-commerce and distributor partnerships may enhance market reach. Management changes and operational relocations suggest a strategic refocus. The patent portfolio and regulatory approvals support product differentiation.

RemSleep operates with a low current ratio of 0.47 and reported a net loss in Q1 2026, indicating liquidity and profitability challenges. The company is transitioning its business model and faces execution risks in scaling e-commerce and distributor sales. Management changes and operational relocations may introduce transitional risks. The competitive medical device market and early commercial stage present uncertainties.

RemSleep's moat is primarily based on its FDA-cleared medical device technology for sleep apnea treatment and its patent portfolio protecting the DeltaWave system. The company's regulatory approvals and product launch progress provide barriers to entry. However, the medical device market is competitive, and the company is in early commercial stages with evolving distribution channels.

• Liquidity Risk: The company has a current ratio of 0.47 and a cash ratio of 0.26 as of March 31, 2026, indicating limited short-term liquidity to cover current liabilities.
• Profitability Risk: RemSleep reported a net loss of $289,924 for Q1 2026, reflecting ongoing operating losses during early commercialization.
• Execution Risk: Transitioning from a retail walk-in model to e-commerce and distributor-based sales involves operational and market execution challenges.
• Management Transition Risk: The passing of the founder and appointment of a new CEO may impact strategic continuity and operational stability.
• Regulatory and Market Risk: The medical device market is competitive, and ongoing regulatory compliance and market acceptance are critical for commercial success.

• RemSleep Holdings Inc. is a smaller reporting company incorporated in Nevada with principal executive offices in Florida.
• The company develops and commercializes the DeltaWave(TM) CPAP nasal pillows system, a medical device for sleep apnea treatment.
• RemSleep received FDA 510(k) clearance for the DeltaWave product and has expanded FDA clearances for the nasal pillow system.
• The company announced the full commercial launch of DeltaWave in February 2026 and outlined a commercial strategy for Q1 2026 including expanded FDA applications, B2B launch preparation, and institutional market entry.
• RemSleep transitioned its business model from a retail walk-in model in Georgia to an e-commerce and e-retail sales channel model with a new warehouse in Florida to support nationwide and international sales.
• The company experienced a management change with the passing of founder Thomas Wood and appointment of Jeffrey Marshall as CEO in March 2026.
• RemSleep has entered formal agreements with major distributors to support product distribution.
• Financial figures as of March 31, 2026, include cash and equivalents of $87,953, current assets of $160,809, current liabilities of $342,275, resulting in a current ratio of 0.47 and a cash ratio of 0.26.
• The company reported a net loss of $289,924 for Q1 2026 and revenue of $16,721 for FY 2025.
• No material legal proceedings or claims are pending or threatened against the company or its officers.
• The company has taken steps to improve compliance with SEC filing timelines and re-engaged auditors and accountants as of June 2026.